This clinical trial is focused on studying the effects of a treatment called Pollinex Quattro Plus 1.0 mL Birch for people who experience seasonal allergic rhinitis and/or rhinoconjunctivitis due to exposure to birch pollen. Seasonal allergic rhinitis is commonly known as hay fever, which causes symptoms like sneezing, a runny or blocked nose, and itchy eyes. Rhinoconjunctivitis includes these symptoms along with eye irritation. The treatment being tested is given as a subcutaneous injection, which means it is injected under the skin.
The purpose of this study is to evaluate how effective and safe the PQ Birch treatment is for individuals affected by birch pollen allergies. Participants in the study will receive either the PQ Birch treatment or a placebo, which is a substance with no active medication. The study is designed to be randomised and double-blind, meaning neither the participants nor the researchers know who is receiving the actual treatment or the placebo, to ensure unbiased results.
Throughout the study, participants will attend several visits where they will receive injections and have their health monitored. The study will last for a period of time that includes the birch pollen season, allowing researchers to observe the treatment’s effects during peak allergy times. The main goal is to see if the treatment can reduce the symptoms of hay fever and improve the quality of life for those affected by birch pollen allergies.
Austria 
Germany 
Poland 
